Microwave Ablation of Liver, Kidney and Lung Lesions: One-Month Response and Manufacturer's Charts' Reliability in Clinical Practice.

Microwave ablation systems allow for performing tumoral destruction in oncology. The objective of this study was to assess the early response and reliability of the microwave ablation zone size at one month for liver, kidney and lung lesions, as compared to the manufacturer's charts. Patients who underwent microwave ablation with the EmprintTM ablation system for liver, kidney and lung lesions between June 2016 and June 2018 were retrospectively reviewed. Local response and ablation zone size (major, L , and minor, l , axes) were evaluated on the one-month follow-up imaging. Results were compared to the manufacturers' charts using the Bland-Altman analysis. Fifty-five patients (mean age 68 ± 11 years; 95 lesions) were included. The one-month complete response was 94%. Liver ablations showed a good agreement with subtle, smaller ablation zones ( L : -2 ± 5.7 mm; l : -5.2 ± 5.6 mm). Kidney ablations showed a moderate agreement with larger ablations for L ( L : 8.69 ± 7.94 mm; l : 0.36 ± 4.77 mm). Lung ablations showed a moderate agreement, with smaller ablations for l ( L : -5.45 ± 4.5 mm; l : -9.32 ± 4.72 mm). With 94% of early complete responses, the system showed reliable ablations for liver lesions, but larger ablations for kidney lesions, and smaller for lung lesions.